Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS

Inebilizumab stands apart from other generalized myasthenia gravis (gMG) treatments not just in how often it's given, but in what it targets, said Richard Nowak, MD, MS, associate professor of neurology at Yale School of Medicine and global principal investigator of the MINT trial. Its trial also didn't require patients to first fail other MG therapies, unlike typical payer step-therapy rules.

Targeting the Antibody Factories

Inebilizumab is the first-in-class CD19 B-cell-directed therapy for generalized myasthenia gravis, approved by the FDA as of late 2025. Rather than broadly suppressing the immune system, it targets the cells that produce autoantibodies directly, hitting what Nowak called the "upstream immunomechanisms of disease" rather than downstream effects, and setting it apart from the other categories of targeted therapy already available for autoimmune myasthenia. It's also dosed just twice a year, a substantially different administration schedule than many other options for generalized MG.

"It really gets at the factories of antibody, and in this case, autoantibody production," Nowak said.

No Step-Therapy Requirement in the Trial

Nowak also pushed back on the idea that inebilizumab fits into a clear treatment sequence. MINT and many of the other registrational trials behind recent MG approvals weren't designed around a step-therapy model, he said, instead enrolling patients with disease activity or uncontrolled symptoms, including measurable weakness on exam. Eligibility was based on active disease state, not on whether a patient had already tried and failed a specific prior treatment.

"This study was not restricted to patients that have necessarily trialed and failed XYZ therapy," Nowak said.

Combined with trial data showing reduced exacerbation and rescue therapy risk even as prednisone doses were tapered, inebilizumab adds a genuinely different option to the MG treatment landscape rather than another entry in an established sequence. For physicians, that means weighing the drug on its own mechanism and evidence, alongside whatever therapies a given patient may or may not have already tried, rather than assuming it only belongs after other options have failed.